REGENXBIO Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by REGENXBIO Inc. on August 5, 2016. The filing primarily addresses two events: the announcement of financial results for the quarter ended June 30, 2016, and changes to the Board of Directors effective August 5, 2016.
Financial Metrics
The filing references a press release (Exhibit 99.1) containing the results of operations and financial condition for the quarter ended June 30, 2016. However, the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these details.
Material Changes and Corporate Governance
- Director Departure: Camille Samuels resigned from the Board of Directors effective immediately on August 5, 2016, to devote full-time efforts to other commitments.
- Director Election: Daniel J. Abdun-Nabi was elected as a Class I director and member of the Audit Committee effective immediately to fill the vacancy left by Ms. Samuels. His initial term expires at the 2019 annual meeting.
- Compensation for New Director:
- Granted an option to purchase 25,000 shares of common stock at an exercise price of $8.69 per share (closing price on August 5, 2016).
- Option vests in equal monthly installments over three years, with acceleration upon change of control or death.
- Annual retainer of $35,000 for Board service and an additional $7,500 for Audit Committee service.
- Eligible for an annual option to purchase 12,500 shares starting in 2017, vesting over one year.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future performance, or a discussion of risks and contingencies within the body of the 8-K. The financial results and related commentary are contained in the referenced press release (Exhibit 99.1).
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended June 30, 2016, by reviewing the press release attached as Exhibit 99.1, as this 8-K does not list the figures.
- Confirm the vesting schedule and exercise price ($8.69) of the stock options granted to new director Daniel J. Abdun-Nabi.
- Note that the financial information in Item 2.02 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Review the Company's definitive proxy statement filed on April 18, 2016, for further details on the non-employee director compensation program.